KALBE FARMA sees a downgrade to Neutral on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of KALBE FARMA (ID), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date February 18, 2022, the closing price was IDR 1,600.00 and its target price was estimated at IDR 1,440.99.P.T. Kalbe Farma is a pharmaceutical company based in Indonesia. Co. is engaged in the production, distribution, marketing, and packaging of pharmaceuticals, health foods, and other consumer products. Co.'s consumer health products include over-the-counter (OTC) drugs comprising cough remedies, multivitamins, and acne creams; energy drinks; nutritional products; infant foods; clinical foods for pregnant women and diabetics; and powdered milks for babies, toddlers, and children. Co. provides a range of licensed and generic ethical products spanning various therapeutic categories, including cancers, renal disease, cardiac diseases, and brain trauma.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.